MicroRNA‐483 amelioration of experimental pulmonary hypertension
暂无分享,去创建一个
Chih-Hung Chou | A. Malhotra | Z. Jing | J. Shyy | Brendan Gongol | Z. Li | L. Bai | F. Fan | M. Rabinovitch | Yifei Miao | M. He | Jiao Zhang | Shanshan Chen | Jin Zhang | Xiao-jian Wang | Yuan Shen | Mingxia Gu | Xiaopei Cui | Yuyang Lei | Yangyang He | Hsien-Da Huang | Xiaosong Yan | Yixin Zhang | Yangyang He | Liang Bai
[1] A. Yoganathan,et al. Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1&agr; (Hypoxia-Inducible Factor-1&agr;) Pathway in Endothelial Cells , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[2] G. Simonneau,et al. An overview of the 6th World Symposium on Pulmonary Hypertension , 2019, European Respiratory Journal.
[3] Traci L. Marin,et al. AMP‐activated Protein Kinase Phosphorylation of Angiotensin‐Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension , 2018, American journal of respiratory and critical care medicine.
[4] N. Arnold,et al. MicroRNA-1405 p and SMURF 1 regulate pulmonary arterial hypertension , 2018 .
[5] A. McAlinden,et al. miR‐483 targets SMAD4 to suppress chondrogenic differentiation of human mesenchymal stem cells , 2017, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[6] D. Tarng,et al. MicroRNA-92a Mediates Endothelial Dysfunction in CKD. , 2017, Journal of the American Society of Nephrology : JASN.
[7] S. Chien,et al. VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microRNA secretion and smooth muscle hyperplasia , 2017, Proceedings of the National Academy of Sciences.
[8] J. Kress,et al. EXPERIMENTAL LUNG INJURY REDUCES KRÜPPEL‐LIKE FACTOR 2 TO INCREASE ENDOTHELIAL PERMEABILITY VIA REGULATION OF RAPGEF3‐RAC1 SIGNALING , 2017, American journal of respiratory and critical care medicine.
[9] J. Burns,et al. miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease , 2017, Circulation research.
[10] Jeffrey T Leek,et al. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.
[11] N. Arnold,et al. MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. , 2016, The Journal of clinical investigation.
[12] Héctor Bueno,et al. Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar , 2016 .
[13] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[14] Rui Chen,et al. RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[15] L. Hao,et al. Expression of intronic miRNAs and their host gene Igf2 in a murine unilateral ureteral obstruction model , 2015, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[16] Simon Gibbs,et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.
[17] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[18] M. Capecchi,et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension , 2014, Nature Medicine.
[19] Jianfeng Jin,et al. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice , 2014, Journal of cellular and molecular medicine.
[20] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[21] Toru Satoh,et al. Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.
[22] S. Kauppinen,et al. Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.
[23] Binqing Fu,et al. IGF-1 promotes the development and cytotoxic activity of human NK cells , 2013, Nature Communications.
[24] S. Erzurum,et al. Endothelial Apelin-FGF Link Mediated by MicroRNAs 424 and 503 is Disrupted in Pulmonary Arterial Hypertension , 2012, Nature Medicine.
[25] Yanchun Deng,et al. MiR‐483–5p suppresses the proliferation of glioma cells via directly targeting ERK1 , 2012, FEBS letters.
[26] Brad T. Sherman,et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis , 2012, Bioinform..
[27] Howard Y. Chang,et al. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. , 2011, The Journal of clinical investigation.
[28] H. Ghofrani,et al. Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.
[29] R. Buscà,et al. miR‐483‐3p controls proliferation in wounded epithelial cells , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] L. Chao,et al. Kruppel-like Factor 4 Is a Novel Mediator of Kallistatin in Inhibiting Endothelial Inflammation via Increased Endothelial Nitric-oxide Synthase Expression* , 2009, The Journal of Biological Chemistry.
[31] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.
[32] F. Luscinskas,et al. Isolation and culture of murine heart and lung endothelial cells for in vitro model systems. , 2006, Methods in molecular biology.
[33] W. Seeger,et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.
[34] S. Jayasena,et al. Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.
[35] the original work is properly cited. , 2022 .